A team of investigators conducted a cross-sectional study to compare CSF biomarker patterns in Down syndrome compared with those of autosomal dominant Alzheimer disease mutation carriers.
Down syndrome was examined as a risk factor for death from COVID-19 through an analysis of data from 8.26 million adults.
More than half of individuals with Down syndrome aged 55 years or older have dementia claims and 32.7 percent have Alzheimer disease (AD) claims.
Intensive lowering of ambulatory blood pressure in older patients with hypertension reduced accumulation of small vessel disease in the white matter of the brain.
Most persons with Down syndrome maintain their personal hygiene by age 13 years and work independently by 20 years.
Higher blood pressure was predicted by higher posterior circulation involvement and bilateral disease.
Neurological and neuropsychological examinations were performed to assess intellectual disabilities, and biological assays were performed on collected CSF and plasma.
Updates were published for prenatal diagnostic testing for genetic disorders and screening for fetal aneuploidy.
Mouse models of Down syndrome showed up to 3 times the number of RCAN1 compared to normal chromosomes.
The collaborative research effort hopes to identify biomarkers that can be applied to other populations.
